DOCSLIB.ORG

IDI-Annual-Report-2012.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IDI-Annual-Report-2012.Pdf Investing in the Future: Annual Report Impacting Real Lives Infectious Diseases Institute College of Health Sciences, Makerere University Infectious Diseases Institute P.O Box 22418, Kampala, Uganda Tel: +256-414 307 000/312 307 000 Fax : +256 414 307 290 College of Health Sciences, Makerere University Email: [email protected] Website: http://idi.mak.ac.ug 1 1. Senior Management Team IDI Staff Pictures 2. Information Services Team 2 Annual Report 2012 Infectious Diseases Institute 2 Infectious Diseases Institute College Of Health Sciences Makerere University, Kampala, Uganda Infectious Diseases Institute Annual Report 2012 P.O Box 22418, Kampala, Uganda Tel: +256-414 307 000/312 307 000 Fax : +256 414 307 290 3 Email: [email protected] Website: http://idi.mak.ac.ug Vision: A Healthy Africa, free from the burden of Infectious Diseases Mission: To build capacity of health systems in Africa for the delivery of sustainable, high quality care and prevention of HIV/AIDS and related infectious diseases through training, research and advanced clinical services Values: Annual Report 2012 • Caring • Integrity • Excellence • Innovation • Teamwork • Accountability Editorial Team: Alex Coutinho, Angelina Twinomujuni and Diana Asiimwe Bena Photography: Hydrogen Studios Ltd. Design & Print: Nomad Advertising Ltd. Infectious Diseases Institute 4 Acronyms AIDS Acquired Immune Deficiency Syndrome ART Antiretroviral Therapy ATIC AIDS Treatment Information Center CAP College of American Pathologists CDC Center for Disease Control and prevention CNE Continuous Nursing Education CSF Civil Society Basket Fund EARNEST Europe-Africa Research network for Second-line Treatment FP Family Planning FM Flourescence Microscopy GIPA Greater Involvement of People Living with HIV/AIDS HIV Human Immunodeficiency Virus ICEA Integrated Clinic Enterprise Application IDCAP Integrated Infectious Disease Capacity Building Evaluation IDI Infectious Diseases Institute INTERACT Infectious Disease Network for Treatment and Research in Africa I-TECH International Training and Education Center on HIV JUMP Joint Uganda Malaria Training Programme KCCA Kampala Capital City Authority MJAP Mulago-Mbarara Teaching Hospitals’ Joint AIDS Programme MRS Medical Records System MOH Ministry of Health Infectious Diseases Institute MAKCHS Makerere University College of Health Sciences MU-JHU Makerere University - Johns Hopkins University Collaboration PEPFAR US President’s Emergency Plan for AIDS Relief PCT Prevention, Care and Treatment PLHAs People Living with HIV and AIDS PMTCT Prevention of Mother to Child Transmission RRH Regional Referral Hospital Annual Report 2012 SLIPTA Strengthening Laboratory Improvement Processes Towards Accreditation Approach SLMTA Strengthening Laboratory Management Towards Accreditation Approach STI Sexually Transmitted Infections TB Tuberculosis U.S.A United States of America USAID United States Agency for International Development US-DOD United States Department of Defense WHO World Health Organisation 5 Table of Contents Acronyms 5 Foreword by IDI Board Chair 6 Introduction by Executive Director 8 IDI By the Numbers 9 Prevention, Care and Treatment Overview 10 IDI as a Specialised ART Clinic 11 Civil Society Fund/Regional Referral Hospitals Project 11 ART Switch Meetings at IDI 12 GIPA Builds the Skills of Friends at IDI 12 Training Programme Overview 14 Training Overview 14 IDI makes the 10,000th trainee 16 Research Programme Overview 19 Transition in Leadership 20 Profile of Dr Andrew Kambugu and Dr Yuka Manabe 20 Ground-breaking Research Leads to Change in Coartem Label 23 IDI receives ANDI Award 24 Pfizer Global Health Fellows 24 Laboratory Services Programme Overview 25 MU-JHU Core Lab at IDI 25 Laboratory Training Programme 26 Laboratory Outreach Services 27 Outreach Programme Overview 29 Annual Report 2012 IDI-KCCA Capacity Building Collaboration 29 IDI-EKKP: Building Capacity for Scaling Up HIV/AIDS Services 30 Saving Mothers Giving Life (SMGL) Project 33 Awards and Scholarships at IDI 36 Development of IDI Funding Base 39 List of Publications 40 IDI Leadership 44 Infectious Diseases Institute IDI Staff Pictures 45 6 Foreword from the IDI Board Chair his year the College of year and wish them the very best laboratory at IDI for consistently Health Sciences as a part of in their new lives. providing world class laboratory TMakerere University (one of services that support the above Africa’s top ten universities) took I note with satisfaction the (clinical, research and training) part in commemorating 90 years many areas where IDI has made activities. Such quality is what is of the University’s existence. significant progress in the the required standard in all labs The University prides itself in immediate past year and I will throughout this country. In this the great strides that have been point out a few of them; The rapid respect the IDI programme to made in research and innovation evolution of the Prevention, Care support upcountry laboratories and is committed to expanding and Treatment (PCT) programme should continue to be supported its role of training the region’s into a specialist programme that in the best way possible. The human resource. As a part of the supports other hospitals and idea of being mindful of the College of Health Sciences, IDI clinics in Uganda’s capital city, need to lower the cost of in- has played a significant role in Kampala and the rest of the service training of health workers enabling the University achieve country. This has contributed without compromising standards its mission and contribute to its greatly to the continuing through identification and legacy. transformation of the standard implementation of cost-efficient of AIDS care services in Uganda methods should translate into On my own behalf and on including the provision of second more health workers benefiting behalf of the IDI Board I wish line anti-retroviral treatment from this service in the long run. to extend my great appreciation (ART). Equally important is the This is one of many examples as Infectious Diseases Institute to the leadership of IDI and the development of models of care to how IDI is making major efforts entire staff for yet again having that support the public health to be socially accountable. performed so well in the last year approach to HIV care not only at that is covered by this annual the IDI central clinic but to the Globally these are times of report. Success would not many clinics around the country. austerity measures because of have been easy to achieve if it Efforts to provide life skills to an unstable world economy. wasn’t for the wonderful support the patients (Friends) attending Therefore as we begin another which has been extended to the IDI clinic is highly commendable year of anticipated high institution by many partners and as this helps individuals to enjoy productivity we must be mindful funders including the Uganda a much better quality of life. more than ever before of the Government. We cannot take value we get for every shilling Annual Report 2012 such generous support for It is a great pleasure and joy spent. granted and we must strive hard to see IDI become increasing to ensure that in the coming recognized nationally, regionally years we continue to work hard and globally as a center of and ensure great returns on this excellence in research and as investment. The Board welcomes a training base for doctoral the new staff who have joined IDI students and in the past year IDI at whatever level and wish them has graduated 6 PhD scholars a very enjoyable and productive who are already been recognized Nelson Sewankambo stay. We also extend our thanks globally for their scholarship Principal, College of Health to those staff whose service to and publications. I must also Sciences Makerere University IDI ended in the course of last pay tribute to the MUH-JHU Board Chairman, IDI 7 Introduction from the IDI Executive Director DI is proud to present this In the end though all that we do 2012 report to its founders, is about people and the report Ibeneficiaries, partners and provides stories and perspectives staff. The report documents the from our beneficiaries, from our continued growth and diversity scholars and from our partners. of IDI programs and highlights The organizational culture of the return on investments made; IDI has “infected” so many like the 6 PhD scholars who other individuals and we present have been part of our Research some of these “heroes from the Capacity building program frontline”. for the past 5 years. IDI is an innovative part of Makerere As we go to press IDI has for “In the end though, University and the College of the past few months worked all that we do is about Health Sciences and one of our with Kibaale District, MOH, primary obligations is to build WHO, MSF, Uganda Red cross people and the report intellectual capital for Uganda and other partners to control provides stories and and Africa. This report highlights an Ebola epidemic. IDI staff perspectives from our the growing number of academic were very much at the frontline peer reviewed papers published and putting their lives at risk to beneficiaries, from by the IDI family as well as the help protect fellow Ugandans. our scholars and from diverse nature of our capacity This is the spirit of who we are our partners. The building programs which this at IDI – working in partnership, year recorded the 10,000th responding to challenges, organizational culture trainee. innovating solutions and helping of IDI has “infected” so to build and improve systems. many other individuals In the past 4 years there has been a deliberate effort to take IDI I thank Makerere University, and we present some of excellence and systems building the IDI Board, the IDI donors, Annual Report 2012 these “heroes from the approaches out to the frontlines; the IDI staff and volunteers frontline”.” in the districts and smaller health and all our beneficiaries for facilities.
Load more

Recommended publications
  • Infected ART Naïve Patients at Mulago Hospital
    Kiggundu et al. BMC Nephrology (2020) 21:440 https://doi.org/10.1186/s12882-020-02091-2 RESEARCH ARTICLE Open Access Prevalence of microalbuminuria and associated factors among HIV − infected ART naïve patients at Mulago hospital: a cross-sectional study in Uganda Thomas Kiggundu1,2* , Robert Kalyesubula1,3, Irene Andia-Biraro1, Gyaviira Makanga1,4 and Pauline Byakika-Kibwika1,5 Abstract Background: HIV infection affects multiple organs and the kidney is a common target making renal disease, one of the recognized complications. Microalbuminuria represents an early, important marker of kidney damage in several populations including HIV-infected antiretroviral therapy (ART) naïve patients. Early detection of microalbuminuria is critical to slowing down progression to chronic kidney disease (CKD) in HIV-infected patients, however, the burden of microalbuminuria in HIV-infected antiretroviral therapy (ART) naïve patients in Uganda is unclear. Methods: A cross-sectional study was conducted in the Mulago Immune suppression syndrome (ISS) clinic among adult HIV − infected ART naïve outpatients. Data on patient demographics, medical history was collected. Physical examination was performed to assess body mass index (BMI) and hypertension. A single spot morning urine sample from each participant was analysed for microalbuminuria using spectrophotometry and colorimetry. Microalbuminuria was defined by a urine albumin creatinine ratio (UACR) 30-299 mg/g and macroalbuminuria by a UACR > 300 mg/g. To assess the factors associated with microalbuminuria, chi-square, Fisher’s exact test, quantile regression and logistic regression were used. Results: A total of 185 adult participants were consecutively enrolled with median age and CD4+ counts of 33(IQR = 28–40) years and 428 (IQR = 145–689) cells/μL respectively.
    [Show full text]
  • Pauline-Byakika-Kwibwika-Idi-Res1.Pdf (480.3Kb)
    SAGE-Hindawi Access to Research Malaria Research and Treatment Volume 2011, Article ID 703730, 5 pages doi:10.4061/2011/703730 Review Article Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals Pauline Byakika-Kibwika,1, 2 Mohammed Lamorde,1, 2 Harriet Mayanja-Kizza,1 Saye Khoo,3 Concepta Merry,1, 2 and Jean-Pierre Van geertruyden4 1 Infectious Diseases Institute and Infectious Diseases Network for Treatment and Research in Africa (INTERACT), Makerere University College of Health Sciences, P.O. Box 7061, Kampala, Uganda 2 Department of Pharmacology and Therapeutics, Trinity College Dublin 2, Ireland 3 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX, UK 4 International Health, Epidemiology en Social Medicine, Universiteit Antwerpen, Universiteitsplein 1, 2610 Antwerp, Belgium Correspondence should be addressed to Pauline Byakika-Kibwika, [email protected] Received 14 December 2010; Accepted 14 February 2011 Academic Editor: Neena Valecha Copyright © 2011 Pauline Byakika-Kibwika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Treatment of malaria in HIV-infected individuals receiving antiretroviral therapy (ART) poses significant challenges. Artemether- lumefantrine (AL) is one of the artemisisnin-based combination therapies recommended for treatment of malaria. The drug combination is highly efficacious against sensitive and multidrug resistant falciparum malaria. Both artemether and lumefantrine are metabolized by hepatic cytochrome P450 (CYP450) enzymes which metabolize the protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) used for HIV treatment.
    [Show full text]
  • DISSERTATION___Louis Nyende.Pdf
    MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES PREVALENCE AND FACTORS ASSOCIATED WITH RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO COMMUNICABLE DISEASE CLINIC. BY DR. LOUIS NYENDE, MBChB (MUK) REG NO 2015/HD07/1323U SUPERVISORS: 1. ASSOCIATE PROF PAULINE BYAKIKA-KIBWIKA (MBChB, MSc, MMed, PHD) 2. Dr. EMMANUEL SEKASANVU (MBChB, MMed, FISN) 3. Dr. KALYESUBULA ROBERT (MBChB, MMed, FISN) RESEARCH DISSERTATION SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF A DEGREE OF MASTERS OF MEDICINE IN INTERNAL MEDICINE OF MAKERERE UNIVERSITY KAMPALA ©APRIL 2018 i DEDICATION I dedicate this work to my lovely wife Susan; and our dear children Louise, Leticia (RIP), Lisa and Blessing. ii ACKNOWLEDGEMENTS Special thanks go to my supervisors, Assoc. Professor Pauline Byakika, Dr. Emmanuel Sekasanvu and Dr. Robert Kalyesubula for their continued advice and guidance. I am also very grateful to the following: Prof. Moses Kamya, Prof Harriet Mayanja and Dr. Deo Wabwire for inspiring me to do internal medicine Dr. Gyaviira Makanga for the advice, guidance and editing Mr. Kalibaala Dennis for the statistical work Mulago-KCCA project for the scholarship award to cater for tuition and functional fees RASHOTS CKD project for the research grant award Apollo Muramuzi,MaryNamuli, Nalongo Irene and the staff of Kiruddu -Mulago hospital infectious diseases Clinic for their assistance in the data collection All the patients attending the Infectious diseases clinic in Mulago communicable disease clinic who voluntarily consented to participate in this study, thank you for accepting to be part of this study. My classmates- Katuramu,Iraguha,Owachi,Okello,Baluku,Mubangizi,Nakidde,Nakagayi & Namukasa for making MMed memorable.
    [Show full text]
  • High CD56 CD16 Natural Killer (NK) 14
    Bayigga et al. BMC Immunology 2014, 15:2 http://www.biomedcentral.com/1471-2172/15/2 RESEARCH ARTICLE Open Access High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort Lois Bayigga1, Rose Nabatanzi1, Prossy Naluyima Sekiziyivu2, Harriet Mayanja-Kizza3, Moses R Kamya3, Andrew Kambugu4, Joseph Olobo1, Agnes Kiragga4, Sam Kirimunda1, Moses Joloba1 and Damalie Nakanjako3,4* Abstract Background: Up to 40% of HIV-infected individuals receiving Highly Active Antiretroviral Therapy (HAART) have poor CD4+ T-cell recovery. The role of natural killer (NK) cells in immune recovery during HAART is not well understood. We described the profiles of NK cell subsets and their expression of activating receptor, NKG2D and cytotoxicity receptor NKp46 among suboptimal immune responders to despite four years of suppressive HAART. Methods: A case control study utilized frozen peripheral blood mononuclear cells (PBMC) from a cohort of HIV-infected adults that initiated HAART in 2004/5, at CD4 < 200 cells/μl. Cases were ‘suboptimal’ responders; patients within the lowest quartile of CD4+ T-cell reconstitution, with a median CD4 count increase of 129 (-43-199) cells/μl (difference between CD4 count at baseline and after 4 years of HAART) and controls were ‘super-optimal’ responders; patients within the highest quartile of CD4 T-cell reconstitution with a median CD4 count increase of 528 (416-878) cells/μl). Expression of NK cell lineage markers (CD56+/-CD16+/-) and receptors NKG2D and NKp46, was measured among PBMC from 29 cases of ‘suboptimal’ responders’ and 23 controls of ‘super-optimal responders’,and compared among ‘suboptimal’ and ‘super-optimal’ responders.
    [Show full text]
  • JCRC at 25 Years Magazine
    JCRC@25 The birth, growth and evolution of the centre A successful journey that started 25 years ago Testimonies from the beneficiaries What the partners say JCRC @25 Contents eDiToR: Conan Businge Messages (Conan Events Co Ltd) Message from Chairman Board 4 Message from Executive Director 6 DeSign & LAYoUT Diana Kambedha Carol Kabega Features JCRC’s 25-year journey 10 Abou Kisige A story of success and great sacrifice 11 Courtesy Photos cooRDinAToR Fred Byaruhanga Profiles JcRc Board members of the years 8 coMMUnicATionS TeAM 12 Christine Matama Senior management All rights reserved. ©2016 Pictorial Reproduction in whole or in part without written permission is strictly Around JCRC 25 prohibited. JCRC, Plot 101, Lubowa E s t a t e s , O ff E n t e b b e R o a d Partners P.O. Box 10005, Kampala, Uganda UK Medical research Council Tel: 256-414-201147/48 Clinical Trail Unit 31 Fax: 256-414-342632 E-Mail: [email protected] Website: http://www.jcrc.co.ug Interviews With Dr James Makumbi 32 With Dr Justine Jita 33 Research JCRC publications 36 JCRC @25 2 JCRC @25 Contents eDiToR: Conan Businge Messages (Conan Events Co Ltd) Message from Chairman Board 4 Message from Executive Director 6 DeSign & LAYoUT Diana Kambedha Carol Kabega Features JCRC’s 25-year journey 10 Abou Kisige A story of success and great sacrifice 11 Courtesy Photos cooRDinAToR Fred Byaruhanga Profiles JcRc Board members of the years 8 coMMUnicATionS TeAM 12 Christine Matama Senior management All rights reserved. ©2016 Pictorial Reproduction in whole or in part without written permission is strictly Around JCRC 25 prohibited.
    [Show full text]
  • A Media Handbook for HIV Vaccine Trials for Africa Acknowledgements
    A Media Handbook for HIV Vaccine Trials for Africa Acknowledgements The Media Handbook for HIV Vaccine Trials for Africa was written by Yinka Adeyemi with guidance and direction from Bunmi Makinwa of the department of Policy, Strategy and Research, Dr Jose Esparza, Dr Saladin Osmanov, Claire Pattou, and Coumba Touré of the World Health Organization (WHO)/Joint United Nations Programme on HIV/AIDS (UNAIDS), HIV Vaccine Initiative. We would like to acknowledge the following individuals for their valuable comments and contributions to this handbook: Dr Alashle Abimiku, Dr Omu Anzala, Dr Carlos Arnaldo, Dr Courtney Batholomew, Janet Frohlich, Dr D. A. Gangakhedar, Dr Rodney Hoff. Patrick Jabani, Bachi Karkaria, Dr Tom LaSalvia, Dr Chewe Luo, Nebat Mbewe, Dr Rosemary Musonda, Binod Mahanty, Dr Roy Mugerwa, Ronaldo Mussauer de Lima, Omololu Falobi, Otula Owuor, Kirk Pereira, Dr John Rwomushana, Mario Scheffer, Jaya Shreedhar, Judith Soal, Dr Prasert Thongcharoen, Kathy Ann Waterman and Victor Zonana. The section on Communication and vaccine trials in Thailand (Appendix 1) is based on a UNAIDS report by Nusara Thaitawat, while that on Communication issues in vaccine trials in Uganda (Appendix 2) is based on a UNAIDS report by Ann Fieldler. The section on Communication and preparations for HIV vaccine trials in Kenya (Appendix 3) is by Otula Owuor. A number of fictitious people and organizations are used for illustrative purposes within the text. Any reference to actual persons or organizations is purely coincidental. UNAIDS/01.05E (English original, February 2001) ISBN 92-9173-021-1 © Joint United Nations Programme on HIV/AIDS The designations employed and the presentation of the (UNAIDS) 2001.
    [Show full text]
  • Career Development for Infection and Immunity Research in Uganda
    AAS Open Research AAS Open Research 2020, 3:26 Last updated: 02 JUL 2020 RESEARCH ARTICLE Career development for infection and immunity research in Uganda: a decade of experience from the Makerere University – Uganda Virus Research Institute research and training programme [version 1; peer review: 1 approved] Damalie Nakanjako 1,2, Flavia Zalwango3, Pamela Wairagala3, Fiona Luboga1, Irene Andia Biraro 1,2, Victoria Diana Bukirwa1, Mary Gorrethy Mboowa1, Steve Cose1,3, Janet Seeley 3,4, Alison Elliott 1,3 1Makerere University-Uganda Virus Research Institute Infection and Immunity (MUII), Uganda Virus Research Institute, Entebbe, Uganda 2Department of Medicine, School of Medicine, Makerere University, College of Health Sciences, Kampala, Uganda 3Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit,, Uganda Virus Research Institute, Entebbe, Uganda 4Global Health and Development Department, London School of Hygiene and Tropical Medicine, London, UK First published: 24 Jun 2020, 3:26 Open Peer Review v1 https://doi.org/10.12688/aasopenres.13066.1 Latest published: 24 Jun 2020, 3:26 https://doi.org/10.12688/aasopenres.13066.1 Reviewer Status Abstract Invited Reviewers Background: The Makerere University/Uganda Virus Research Institute 1 (UVRI) Centre of Excellence for Infection & Immunity Research and Training (MUII) is a collaborative programme supporting excellence in version 1 Infection and Immunity (I&I) research in Uganda. Set up in 2008, MUII aims 24 Jun 2020 report to produce internationally competitive Ugandan and East African I&I research leaders, and develop human and infrastructural resources to support research and training excellence. We undertook an internal evaluation of MUII’s achievements, challenges and lessons learned 1 Yohana Mashalla , University of Botswana, between August 2008 and December 2019, to inform programmes seeking Gaborone, Botswana to build Africa’s health research expertise.
    [Show full text]
  • Serena Hotel and Conference Centre Kampala, Uganda May 26–27, 2011 Table of Contents
    Program Serena Hotel and Conference Centre Kampala, Uganda MAY 26–27, 2011 Table of Contents Welcome Letter . 3 Acknowledgements . 4 General Information . 5 Agenda . 9 u Wednesday, May 25, 2011 . 9 u Thursday, May 26, 2011 . 9 u Friday, May 27, 2011 . .11 Conference Centre Floor Plan . 13 Abstracts . 14 Attendee List . 38 Attendee Collaboration Information . 47 SUB-SAHARAN AFRICA CFAR CONFERENCE 2011 1 Dear CFAR Colleagues and Partners! On behalf of the U .S . National Institutes of Health-sponsored Centers for AIDS Research, and Makerere University’s Infectious Diseases Institute, welcome to Kampala! It is our pleasure and honor to have you join us for the 2011 Sub-Saharan Africa CFAR Conference as we gather to feature some of the important research being conducted by African investigators collaborating with the 21 Centers for AIDS Research (CFARs) . Our Conference Steering Committee is planning an exciting program focusing on three priority themes: u Integrating Treatment and Prevention in HIV Care u HIV Comorbidities u HIV and Women Through a combination of plenary and poster presentations, panel discussions, and networking sessions, this meeting will present a unique opportunity for both scientific and information exchange . A special effort will be made to provide a platform for sharing information on existing scientific resources and infrastructure at leading African institutions that support AIDS research and training – a critical prerequisite for the exchange of scientific resources, capacity building, and the fostering of new collaborations among African institutions . The conference has already generated much energy and interest . We envision this momentum leading to the emergence of an African-led network that will build on existing collaborations and begin to explore potential synergies with new partners – including other CFARs, other complementary networks active in Africa, and in particular, South-South partnerships among African institutions – to strengthen the community of science on the continent .
    [Show full text]
  • Scientific Considerations for the Regulation and Clinical Evaluation of HIV/AIDS Preventive Vaccines
    WHO–UNAIDS REPORT Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines Reportà from a WHO-UNAIDS Consultation 13–15 March 2001, Geneva, Switzerland The consultation was jointly organized by the WHO-UNAIDS HIV Vaccine Initiative and the Quality Assurance and Safety of Biologicals Team of the World Health Organization (WHO). Thirty-four experts from 16 developed and developing countries attended the meeting, bringing together expertise from academic institutions, clinical trial centres, national and international regulatory authorities. Representatives of major pharmaceutical companies were also invited. The primary objective of the meeting was to identify gaps that need to be addressed from regulatory perspective to ensure appropriate progress of HIV vaccine develop- ment from basic research to human trials, licensing and future application, with a special focus on needs of developing countries. As a result of discussions, the following priority needs were identified and recommen- dations were made in order to establish an appropriate regulatory framework for the development and evaluation of preventive HIV/AIDS vaccines, which were divided in two main areas: (a) standardization and control of candidate HIV/AIDS vaccines, and (b) approaches to the conduct of clinical trials of candidate HIV/AIDS vaccines.& 2002 Lippincott Williams & Wilkins AIDS 2002, 16:W15–W25 Keywords: HIV/AIDS vaccines, product development, clinical trials, regulatory requirements Introduction the best hope of prevention
    [Show full text]
  • HIV/AIDS and Governance in Uganda and Senegal’ P.I
    James Putzel, ‘HIV/AIDS and Governance in Uganda and Senegal’ p.i Institutionalising an Emergency Response: HIV/AIDS and Governance in Uganda and Senegal1 A report submitted to the Department for International Development May 2003 Dr. James Putzel 1 All comments would be welcome by the author: [email protected]. I would like to thank all those in Uganda and Senegal who spared valuable time to meet with me and steer me towards important documentation. I would like to thank all those who provided comments and criticisms on earlier drafts including Tim Allen, Tony Barnett, Charles Becker, Victoria Brittain, Ben Dickson, Garth Glentworth, Julian Lambert, F. Golooba Mutebi, Ken Shadlen, Angela Spilsbury, Sue Unsworth and Alan Whiteside. I am especially grateful to Sarah Hearn for both comments and support throughout this study. Since I have accepted some suggestions and rejected others, I assume full responsibility for what appears in the following pages. James Putzel, ‘HIV/AIDS and Governance in Uganda and Senegal’ p.ii Table of contents Executive Summary................................................................................................. iii Acronyms..................................................................................................................vi 1. Introduction............................................................................................................1 1.1 Why was the international community late?....................................................2 1.2 Why look at governance?.................................................................................3
    [Show full text]
  • Protest UKRI Funding Cuts
    18th March 2021 Rt Honourable Dominic Raab, Secretary of State for Foreign, Commonwealth and Development Affairs Rt Hon Rishi Sunak, Chancellor of the Exchequer Dear Mr Raab and Mr Sunak, Subject: Cutting UKRI Funding is unacceptable and counterproductive to UK and global interests We are writing in response to the letter issued by the UKRI on 11th March 2021 informing UK higher education institutions that it would be reducing the allocation to UKRI ‘significantly’ in light of the UK government’s decision to suspend its Official Development Assistance (ODA) commitment to 0.7% of GNI. As people employed in UK academic institutions working on global health and as their research colleagues, partners and collaborators across the globe, we, the undersigned, urge the government to reconsider this decision. The consequences of the decision are far-reaching for the health and wellbeing of some of the poorest, most vulnerable and marginalised members of our global community, and for the creation of the next generation of young researchers in ODA-recipient countries and in the UK, individuals whose skills will be essential if we are to find solutions to the many challenges facing our world. We are of course well aware of the impact of COVID-19 on people and economies, and understand that difficult decisions are having to be made as the UK builds back better and fairer in the coming years. However, we are dismayed that the people likely to suffer most from the decision announced on March 11th are the ultimate beneficiaries of UKRI-funded research programmes - which address some of the world’s most complex and challenging global health problems.
    [Show full text]
  • Croi 2021 Program Committee
    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
    [Show full text]